PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 160 participants.
Also called NCT04971720
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose other
- Phase
- Phase 2/3
- Enrolled
- 160 participants
- Registry
-
NCT04971720
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT04971720. Randomized; quadruple masking; primary purpose other. Start 2022-02-18 (actual); primary completion 2027-01-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis
- Acronym
- PRECISION-BP
- Condition
- Obesity
- Condition
- Cardiovascular Diseases
- Condition
- Hypertension
- Condition
- Nocturnal Blood Pressure
- Condition
- Natriuretic Peptides
- Condition
- Renin-Angiotensin-Aldosterone System
- Intervention (Drug)
- Sacubitril-Valsartan 49 Mg-51 Mg Oral Tablet
- Intervention (Drug)
- Valsartan 80 mg Oral Tablet
- Lead sponsor
- University of Alabama at Birmingham
- Collaborator
- National Heart, Lung, and Blood Institute (NHLBI)
Record details
- Record id
cardio:ct-nct04971720- Content hash
8399c0dd92d4f8d3c43c3cf3f9667c0f2b5171f2bf09415554eb825d48231b96